Literature DB >> 21393343

Trastuzumab beyond progression in retrospective analyses: an issue of equal opportunities.

Filippo Montemurro, Stefania Redana, Elena Geuna, Andrea Milani, Valentina Rossi, Rossella Martinello, Giorgio Valabrega, Massimo Aglietta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21393343      PMCID： PMC3228112          DOI： 10.1634/theoncologist.2010-0329

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  3 in total

1.  Treatment beyond progression: is it moving from belief to evidence?

Authors:  Rinat Yerushalmi; Karen Gelmon
Journal:  Oncologist       Date:  2010-07-29

2.  Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy.

Authors:  Filippo Montemurro; Michela Donadio; Matteo Clavarezza; Stefania Redana; Maria Elena Jacomuzzi; Giorgio Valabrega; Saverio Danese; Guido Vietti-Ramus; Antonio Durando; Marco Venturini; Massimo Aglietta
Journal:  Oncologist       Date:  2006-04

3.  Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.

Authors:  Jean-Marc Extra; Eric C Antoine; Anne Vincent-Salomon; Thierry Delozier; Pierre Kerbrat; Anne Bethune-Volters; Jean-Paul Guastalla; Marc Spielmann; Louis Mauriac; Jean-Louis Misset; Daniel Serin; Mario Campone; Christophe Hebert; Céline Remblier; Loïc Bergougnoux; Frank Campana; Moïse Namer
Journal:  Oncologist       Date:  2010-07-29
  3 in total
  1 in total

1.  Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?

Authors:  Helmy M Guirgis
Journal:  J Oncol Pract       Date:  2012-07       Impact factor: 3.840
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.